These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 12523873)
1. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. Caro JJ; Ward A; Levinton C; Robinson K J Clin Psychiatry; 2002 Dec; 63(12):1135-9. PubMed ID: 12523873 [TBL] [Abstract][Full Text] [Related]
2. Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Fuller MA; Shermock KM; Secic M; Grogg AL Pharmacotherapy; 2003 Aug; 23(8):1037-43. PubMed ID: 12921249 [TBL] [Abstract][Full Text] [Related]
3. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. Gianfrancesco FD; Grogg AL; Mahmoud RA; Wang RH; Nasrallah HA J Clin Psychiatry; 2002 Oct; 63(10):920-30. PubMed ID: 12416602 [TBL] [Abstract][Full Text] [Related]
4. Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States. Feldman PD; Hay LK; Deberdt W; Kennedy JS; Hutchins DS; Hay DP; Hardy TA; Hoffmann VP; Hornbuckle K; Breier A J Am Med Dir Assoc; 2004; 5(1):38-46. PubMed ID: 14706127 [TBL] [Abstract][Full Text] [Related]
5. Glucose intolerance with atypical antipsychotics. Hedenmalm K; Hägg S; Ståhl M; Mortimer O; Spigset O Drug Saf; 2002; 25(15):1107-16. PubMed ID: 12452735 [TBL] [Abstract][Full Text] [Related]
6. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. Koro CE; Fedder DO; L'Italien GJ; Weiss SS; Magder LS; Kreyenbuhl J; Revicki DA; Buchanan RW BMJ; 2002 Aug; 325(7358):243. PubMed ID: 12153919 [TBL] [Abstract][Full Text] [Related]
7. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Koro CE; Fedder DO; L'Italien GJ; Weiss S; Magder LS; Kreyenbuhl J; Revicki D; Buchanan RW Arch Gen Psychiatry; 2002 Nov; 59(11):1021-6. PubMed ID: 12418935 [TBL] [Abstract][Full Text] [Related]
8. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575 [TBL] [Abstract][Full Text] [Related]
9. Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine. Schillevoort I; de Boer A; Herings RM; Roos RA; Jansen PA; Leufkens HG Ann Pharmacother; 2001 Dec; 35(12):1517-22. PubMed ID: 11793611 [TBL] [Abstract][Full Text] [Related]
10. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. Carlson CD; Cavazzoni PA; Berg PH; Wei H; Beasley CM; Kane JM J Clin Psychiatry; 2003 Aug; 64(8):898-906. PubMed ID: 12927004 [TBL] [Abstract][Full Text] [Related]
11. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268 [TBL] [Abstract][Full Text] [Related]
12. [Therapy with antipsychotic drugs as a risk factor for diabetes in schizophrenia: a case-control study]. Rubio G; Gómez-de-la-Cámara A; Ledesma F; Burón JA; Rodríguez-Morales A; Martínez-Junquera G; Med Clin (Barc); 2006 Apr; 126(12):441-4. PubMed ID: 16620729 [TBL] [Abstract][Full Text] [Related]
13. The effects of novel antipsychotics on glucose and lipid levels. Wirshing DA; Boyd JA; Meng LR; Ballon JS; Marder SR; Wirshing WC J Clin Psychiatry; 2002 Oct; 63(10):856-65. PubMed ID: 12416594 [TBL] [Abstract][Full Text] [Related]
14. Experience with the atypical antipsychotics--risperidone and olanzapine in the elderly. Madhusoodanan S; Suresh P; Brenner R; Pillai R Ann Clin Psychiatry; 1999 Sep; 11(3):113-8. PubMed ID: 10482120 [TBL] [Abstract][Full Text] [Related]
15. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods. Simpson MM; Goetz RR; Devlin MJ; Goetz SA; Walsh BT J Clin Psychiatry; 2001 Sep; 62(9):694-700. PubMed ID: 11681765 [TBL] [Abstract][Full Text] [Related]
16. Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Gianfrancesco F; Grogg A; Mahmoud R; Wang RH; Meletiche D Clin Ther; 2003 Apr; 25(4):1150-71. PubMed ID: 12809963 [TBL] [Abstract][Full Text] [Related]
17. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Sikich L; Hamer RM; Bashford RA; Sheitman BB; Lieberman JA Neuropsychopharmacology; 2004 Jan; 29(1):133-45. PubMed ID: 14583740 [TBL] [Abstract][Full Text] [Related]
18. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. Meyer JM J Clin Psychiatry; 2002 May; 63(5):425-33. PubMed ID: 12019668 [TBL] [Abstract][Full Text] [Related]
19. Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases. Aubry JM; Simon AE; Bertschy G J Clin Psychiatry; 2000 Sep; 61(9):649-55. PubMed ID: 11030485 [TBL] [Abstract][Full Text] [Related]